

## Verosudil

## Chemical Properties

CAS No. : 1414854-42-4


Formula: C<sub>17</sub>H<sub>17</sub>N<sub>3</sub>O<sub>2</sub>S

Molecular Weight: 327.4

Store at low temperature

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



## Biological Description

Description	Verosudil (AR-12286) is a highly potent Rho kinase (ROCK) inhibitor with a $K_i$ of 2 nM and 2 nM against ROCK1 and ROCK2, respectively. AR-12286 mitigates steroid-induced intraocular pressure in mice by decreasing intraocular pressure through enhanced outflow of aqueous humor via the trabecular meshwork.
Targets(IC50)	ROCK

## Solubility Information

Solubility	DMSO: 45 mg/mL (137.45 mM), Sonication is recommended. ( $< 1$ mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1 mg/mL (3.05 mM), Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

### Preparing Stock Solutions

---

	1mg	5mg	10mg
1 mM	3.0544 mL	15.2718 mL	30.5437 mL
5 mM	0.6109 mL	3.0544 mL	6.1087 mL
10 mM	0.3054 mL	1.5272 mL	3.0544 mL
50 mM	0.0611 mL	0.3054 mL	0.6109 mL

---

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Kopczynski C, Novack GD, Swearingen D, van Haarlem T. Ocular hypotensive efficacy, safety and systemic absorption of AR-12286 ophthalmic solution in normal volunteers. *Br J Ophthalmol.* 2013;97(5):567-572.  
Lin CW, Sherman B, Moore LA, et al. Discovery and Preclinical Development of Netarsudil, a Novel Ocular Hypotensive Agent for the Treatment of Glaucoma. *J Ocul Pharmacol Ther.* 2018;34(1-2):40-51.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481